I invest for long-term total return, prioritizing dividend growth and quality companies trading at bargain valuations, especially during industry downturns. Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in top-tier pharmaceutical stocks due to strong fundamentals and future AI benefits. My quantitative screen highlights six pharma leaders, with Novo Nordisk (NVO) and Merck (MRK) scoring highest across dividends, growth, capital structure, and free cash flow.
Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below historical averages. Despite lowered 2025 guidance and slower growth, core products Ozempic and Wegovy continue to deliver impressive sales and global expansion opportunities. Heavy capital expenditures are temporary, aimed at expanding manufacturing to meet strong demand; long-term free cash flow margins should recover.
Novo Nordisk is still the GLP-1 king, with over 65% market share and blockbuster drugs like Ozempic and Wegovy continuing to drive global growth. The recent stock correction presents a rare long-term buying opportunity, supported by a strong pipeline, manufacturing expansion, and international momentum. The valuation is attractive relative to historical metrics, with a +3% yield and significant room for capital appreciation as demand continues to outpace supply.
![]() NVO In 1 week Announced | Semi Annual | $0.41 Per Share |
![]() NVO 4 months ago Paid | Other | $1.1 Per Share |
![]() NVO 11 months ago Paid | Other | $0.52 Per Share |
![]() NVO 22 Mar 2024 Paid | Other | $0.93 Per Share |
![]() NVO 18 Aug 2023 Paid | Other | $0.44 Per Share |
5 Nov 2025 (In 2 months) Date | | 5.86 Cons. EPS | - EPS |
5 Nov 2025 (In 2 months) Date | | 0.99 Cons. EPS | - EPS |
6 Aug 2025 Date | | 6 Cons. EPS | 5.96 EPS |
7 May 2025 Date | | 0.92 Cons. EPS | 6.53 EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
![]() NVO In 1 week Announced | Semi Annual | $0.41 Per Share |
![]() NVO 4 months ago Paid | Other | $1.1 Per Share |
![]() NVO 11 months ago Paid | Other | $0.52 Per Share |
![]() NVO 22 Mar 2024 Paid | Other | $0.93 Per Share |
![]() NVO 18 Aug 2023 Paid | Other | $0.44 Per Share |
5 Nov 2025 (In 2 months) Date | | 5.86 Cons. EPS | - EPS |
5 Nov 2025 (In 2 months) Date | | 0.99 Cons. EPS | - EPS |
6 Aug 2025 Date | | 6 Cons. EPS | 5.96 EPS |
7 May 2025 Date | | 0.92 Cons. EPS | 6.53 EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Lars Fruergaard Jorgensen CEO | LSE Exchange | US6701002056 ISIN |
DK Country | 77,406 Employees | 18 Aug 2025 Last Dividend | 20 Sep 2023 Last Split | - IPO Date |
Novo Nordisk A/S is an established global pharmaceutical company with a heritage dating back to 1923. With its headquarters in Bagsvaerd, Denmark, the company has a widespread operational reach across Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and other international markets. Novo Nordisk is committed to discovering and developing innovative pharmaceutical products, focusing primarily on Diabetes and Obesity Care, and Rare Disease. The company has carved a niche for itself by not just being a manufacturer but also engaging in the research and development of new pharmaceutical products, ensuring they provide contemporary and efficient solutions to the healthcare challenges of today.
Novo Nordisk A/S offers a comprehensive range of healthcare products and solutions aimed at addressing some of the most challenging diseases. With a focus on quality and innovation, their offerings encompass:
Through a collaboration agreement with Aspen Pharmaceuticals, Novo Nordisk also ensures the production of insulin products, highlighting their commitment to making essential medications accessible. The company's enduring legacy and forward-looking approach have positioned it as a key player in the global pharmaceutical industry, dedicated to improving the lives of patients worldwide.